Scarica l'app Stockscreener
8.11
3.11%
-0.26
Dopo l'orario di chiusura:
8.14
0.03
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$8.37
Aprire:
$8.39
Volume 24 ore:
5.49M
Relative Volume:
1.16
Capitalizzazione di mercato:
$2.50B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-23.85
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-1.93%
1M Prestazione:
+1.25%
6M Prestazione:
+21.04%
1 anno Prestazione:
-22.76%
Intervallo 1D:
$8.07
$8.48
Intervallo di 1 settimana:
$7.965
$8.485
Portata 52W:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.11 | 2.48B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockTrade Analysis Report & Low Drawdown Investment Strategies - newser.com
What earnings revisions data tells us about Amicus Therapeutics Inc.Market Trend Report & Reliable Intraday Trade Plans - newser.com
How to escape a deep drawdown in Amicus Therapeutics Inc.2025 Trading Volume Trends & Comprehensive Market Scan Insights - newser.com
Can volume confirm reversal in Amicus Therapeutics Inc.July 2025 Reactions & Real-Time Stock Movement Alerts - newser.com
Amicus Therapeutics Q2 2025 slides: Revenue grows 18% as rare disease portfolio expands - Investing.com Canada
Earnings call transcript: Amicus Therapeutics reports Q2 2025 earnings, stock dips - Investing.com
Why Amicus Therapeutics Inc. stock is a must watch in 2025July 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryWeekly Stock Report & Community Consensus Stock Picks - newser.com
What Fibonacci levels say about Amicus Therapeutics Inc. reboundPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Will a bounce in Amicus Therapeutics Inc. offer an exitMarket Movers & Risk Controlled Stock Alerts - newser.com
Heatmap analysis for Amicus Therapeutics Inc. and competitorsEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
What macro factors could drive Amicus Therapeutics Inc. (AM6) stock higherJuly 2025 Summary & Accurate Technical Buy Alerts - newser.com
Developing predictive dashboards with Amicus Therapeutics Inc. dataJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Amicus Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Real time scanner hits for Amicus Therapeutics Inc. explainedJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease - Nasdaq
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Q3 EPS Forecast for Amicus Therapeutics Lifted by Analyst - MarketBeat
What Does Wall Street Think About Amicus Therapeutics (FOLD)? - MSN
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy - sharewise.com
Is Amicus Therapeutics Inc AM6 a good long term investmentVWAP Trading Strategies & Consistent Triple Returns - earlytimes.in
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments - Yahoo Finance
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics - Yahoo Finance
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: A Biotech Gem With 88% Potential Upside - DirectorsTalk Interviews
Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Fore - PharmiWeb.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns - TradingView
A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD) - Yahoo Finance
Is Amicus Therapeutics Inc. (AM6) stock a top pick for value investorsWeekly Volume Report & Fast Gain Swing Alerts - newser.com
Market reaction to Amicus Therapeutics Inc.’s recent newsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
How to forecast Amicus Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Needham Upgrades Amicus Therapeutics(FOLD.US) to Buy Rating, Announces Target Price $14 - 富途牛牛
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amicus Therapeutics Inc Azioni (FOLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):